This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
5-MAPB: Difference between revisions
>Brack effects template |
>JohntheCaptain No edit summary |
||
| (21 intermediate revisions by 12 users not shown) | |||
| Line 1: | Line 1: | ||
{{SummarySheet}} | {{SummarySheet}} | ||
{{SubstanceBox/5-MAPB}} | {{SubstanceBox/5-MAPB}} | ||
| Line 5: | Line 5: | ||
'''5-(2-methylaminopropyl)benzofuran''' (abbreviated '''5-MAPB''') is a synthetic [[Psychoactive class::entactogen]] of the substituted [[chemical class::benzofuran]] class of chemicals, which are known to produce [[euphoria|euphoric]], [[entactogen]]ic, [[stimulant|stimulating]] and mildly [[hallucinogen]]ic effects. These include such [[MDA]]-inspired substances as [[5-APB]], [[6-APB]] and [[5-EAPB]], among others. 5-MAPB is the N-methylated form of [[5-APB]], analogously to how [[MDMA]] is the N-methylated form of [[MDA]]. | '''5-(2-methylaminopropyl)benzofuran''' (abbreviated '''5-MAPB''') is a synthetic [[Psychoactive class::entactogen]] of the substituted [[chemical class::benzofuran]] class of chemicals, which are known to produce [[euphoria|euphoric]], [[entactogen]]ic, [[stimulant|stimulating]] and mildly [[hallucinogen]]ic effects. These include such [[MDA]]-inspired substances as [[5-APB]], [[6-APB]] and [[5-EAPB]], among others. 5-MAPB is the N-methylated form of [[5-APB]], analogously to how [[MDMA]] is the N-methylated form of [[MDA]]. | ||
This compound is known for its [[stimulating]], [[euphoria|euphoric]] and [[entactogen]]ic effects that is capable of acting a quasi-substitute for [[MDMA]] proper, which has resulted in its rise in popularity as a [[research chemical]] that is easily accessible through the use of online vendors. It has been sold as a [[designer drug]] since 2010.<ref>EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA | | This compound is known for its [[stimulating]], [[euphoria|euphoric]] and [[entactogen]]ic effects that is capable of acting a quasi-substitute for [[MDMA]] proper, which has resulted in its rise in popularity as a [[research chemical]] that is easily accessible through the use of online vendors. It has been sold as a [[designer drug]] since 2010.<ref>{{Citation | title=EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA | url=https://www.emcdda.europa.eu/publications/implementation-reports/2010}}</ref> | ||
5-MAPB is commonly found as the succinate and hydrochloride salt. The hydrochloride salt is | 5-MAPB is commonly found as the succinate and hydrochloride salt. The hydrochloride salt is 36% more potent by mass so doses should be adjusted accordingly.{{citation needed}} | ||
==Chemistry== | ==Chemistry== | ||
| Line 13: | Line 13: | ||
==Pharmacology== | ==Pharmacology== | ||
5-MAPB is a triple [[reuptake inhibitor]] for the [[monoamines]] [[norepinephrine]], [[dopamine]] and [[serotonin]] as well as being an [[agonist]] for the [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] and [[Serotonin#The_5-HT_system|5-HT<sub>2B</sub>]] [[receptor]]s.<ref>The effects of benzofury (5- | 5-MAPB is a triple [[reuptake inhibitor]] for the [[monoamines]] [[norepinephrine]], [[dopamine]] and [[serotonin]] as well as being an [[agonist]] for the [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] and [[Serotonin#The_5-HT_system|5-HT<sub>2B</sub>]] [[receptor]]s.<ref>{{cite journal | vauthors=((Dawson, P.)), ((Opacka-Juffry, J.)), ((Moffatt, J. D.)), ((Daniju, Y.)), ((Dutta, N.)), ((Ramsey, J.)), ((Davidson, C.)) | journal=Progress in Neuro-Psychopharmacology & Biological Psychiatry | title=The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat | volume=48 | pages=57–63 | date=3 January 2014 | issn=1878-4216 | doi=10.1016/j.pnpbp.2013.08.013}}</ref><ref>{{cite journal | vauthors=((Iversen, L.)), ((Gibbons, S.)), ((Treble, R.)), ((Setola, V.)), ((Huang, X.-P.)), ((Roth, B. L.)) | journal=European Journal of Pharmacology | title=Neurochemical profiles of some novel psychoactive substances | volume=700 | issue=1 | pages=147–151 | date=30 January 2013 | url=https://www.sciencedirect.com/science/article/pii/S0014299912010114 | issn=0014-2999 | doi=10.1016/j.ejphar.2012.12.006}}</ref> It has also been speculated that 5-MAPB acts as a [[releasing agent]] for the previously mentioned [[neurotransmitters]]. | ||
As a result, releasing agents such as [[5-MAPB]] may exert their activity by effectively boosting the levels of the serotonin, norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally clear and reuptake those monoamines from the synaptic cleft. This allows serotonin, dopamine and norepinephrine to accumulate within various reward and cognition-related areas in the brain, resulting in [[stimulation|stimulating]] and [[physical euphoria|euphoric]] effects. | As a result, releasing agents such as [[5-MAPB]] may exert their activity by effectively boosting the levels of the serotonin, norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally clear and reuptake those monoamines from the synaptic cleft. This allows serotonin, dopamine and norepinephrine to accumulate within various reward and cognition-related areas in the brain, resulting in [[stimulation|stimulating]] and [[physical euphoria|euphoric]] effects. | ||
| Line 20: | Line 20: | ||
{{effectStub}} | {{effectStub}} | ||
{{Preamble/SubjectiveEffects}} | {{Preamble/SubjectiveEffects}} | ||
{{effects/base | {{effects/base | ||
|{{effects/physical| | |{{effects/physical| | ||
*'''[[Effect::Stimulation]]''' - In terms of its effects on the user's physical energy levels, 5-MAPB is commonly regarded as significantly less stimulating and energizing than MDMA, while still retaining its core entactogenic effects. Unlike MDMA, which encourages activities such as running, climbing and dancing in a way that makes it a popular choice for musical events such as festivals and raves | *'''[[Effect::Stimulation]]''' - In terms of its effects on the user's physical energy levels, 5-MAPB is commonly regarded as significantly less stimulating and energizing than MDMA, while still retaining its core entactogenic effects. Unlike MDMA, which encourages activities such as running, climbing and dancing in a way that makes it a popular choice for musical events such as festivals and raves, the distinct style of stimulation which 5-MAPB presents can be described as mildly to moderately forced, trending more towards sedation and relaxation. This means that at higher doses, it becomes difficult or impossible to keep still as jaw clenching, involuntarily body shakes and vibrations become present, resulting in an extreme unsteadiness of the hands and a general lack of motor control, though to a far lesser degree than with MDMA. | ||
*'''[[Effect::Increased heart rate]]''' | *'''[[Effect::Increased heart rate]]''' | ||
*'''[[Effect::Dehydration]]''' | *'''[[Effect::Dehydration]]''' | ||
| Line 29: | Line 30: | ||
*'''[[Effect::Temporary erectile dysfunction]]''' | *'''[[Effect::Temporary erectile dysfunction]]''' | ||
*'''[[Effect::Increased perspiration]]''' | *'''[[Effect::Increased perspiration]]''' | ||
*'''[[Effect::Nystagmus]]''' | |||
}} | }} | ||
| Line 38: | Line 40: | ||
|{{effects/cognitive| | |{{effects/cognitive| | ||
The cognitive effects of 5-MAPB are mostly comparable to [[MDMA]], but missing the physical and mental stimulation that would be associated. Instead, it focuses mostly on serotonergic activity, leading to more pronounced feelings of empathy, euphoria and a general relaxed state of mind. At higher dosages, this becomes less apparent as physical and cognitive side effects appear which can result in states of confusion and restlessness perhaps more severe than with MDMA. It also shares many of its effects with [[5-APB]]. | |||
*'''[[Effect::Empathy, love, and sociability enhancement]]''' | *'''[[Effect::Empathy, love, and sociability enhancement]]''' | ||
*'''[[Effect::Focus enhancement]]''' | *'''[[Effect::Focus enhancement]]''' | ||
| Line 67: | Line 71: | ||
{{#ask: [[Category:5-MAPB]][[Category:Experience]]|format=ul|Columns=1}} | {{#ask: [[Category:5-MAPB]][[Category:Experience]]|format=ul|Columns=1}} | ||
Additional experience reports can be found here: | Additional experience reports can be found here: | ||
* [https://www.erowid.org/experiences/subs/ | |||
*[https://www.erowid.org/experiences/subs/exp_5MAPB.shtml Erowid Experience Vaults: 5-MAPB] | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
| Line 88: | Line 93: | ||
{{DangerousInteractions/Intro}} | {{DangerousInteractions/Intro}} | ||
{{DangerousInteractions/Stimulants|self=5-MAPB}} | {{DangerousInteractions/Stimulants|self=5-MAPB}} | ||
{{DangerousInteractions/MAOI|nt=dopamine}} | {{DangerousInteractions/MAOI|nt=dopamine}} | ||
====[[Serotonin syndrome]] risk==== | ====[[Serotonin syndrome]] risk==== | ||
{{DangerousInteractions/SerotoninSyndrome}} | {{DangerousInteractions/SerotoninSyndrome}} | ||
==Legal | ==Legal status== | ||
{{legalStub}} | {{legalStub}} | ||
*'''United Kingdom | |||
*'''United States | *'''France''': 5-MAPB is classified as a narcotic since May 9, 2018, alongside other substances derived from benzofuran.<ref>{{cite web|url=https://www.legifrance.gouv.fr/loda/article_lc/LEGIARTI000043529751|title=Article Annexe IV - Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants|publisher=Légifrance|access-date=September 23, 2022|language=fr}}</ref> | ||
*'''Germany''': 5-MAPB is controlled under the NpSG (New Psychoactive Substances Act)<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> as of November 26, 2016.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl116s2615.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl116s2615.pdf%27%5D__1576017393518|title=Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe|publisher=Bundesanzeiger Verlag|access-date=December 18, 2019|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> | |||
*'''Japan''': 5-MAPB is a controlled substance in Japan effective August 15th, 2015.<ref>[https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/ihou-drug/20140815.html "平成26年8月15日付けで以下の21物質が指定薬物に指定されました。（施行日：平成26年8月25日）"] (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved on May 2, 2022.</ref> | |||
*'''Luxembourg:''' 5-MAPB is not cited in the list of prohibited substances<ref>Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie. | <nowiki>http://legilux.public.lu/eli/etat/leg/loi/1973/02/19/n1/jo</nowiki></ref>. Therefore, it is still a legal substance. | |||
*'''Switzerland''': 5-MAPB is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | |||
*'''United Kingdom''': 5-MAPB is a Class B drug.<ref>UK Home Office (2014-03-05). "[https://www.legislation.gov.uk/ukdsi/2014/9780111110904 The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014]". UK Government. Retrieved 2014-03-11.</ref> | |||
*'''United States''': 5-MAPB could be considered an analogue of [[MDA]] and therefore would be covered under the Federal Analogue Act if intended for human consumption. | |||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Designer drug]] | *[[Designer drug]] | ||
| Line 111: | Line 123: | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/5-MAPB 5-MAPB (Wikipedia)] | *[https://en.wikipedia.org/wiki/5-MAPB 5-MAPB (Wikipedia)] | ||
*[https://www.erowid.org/chemicals/5-mapb/ 5-MAPB (Erowid Vault)] | |||
*[https://isomerdesign.com/PiHKAL/explore.php?id=1289 5-MAPB (Isomer Design)] | |||
*[http://www.bluelight.org/vb/threads/548570-The-Big-amp-Dandy-5-MAPB-Thread The Big and Dandy 5-MAPB Thread (Bluelight)] | *[http://www.bluelight.org/vb/threads/548570-The-Big-amp-Dandy-5-MAPB-Thread The Big and Dandy 5-MAPB Thread (Bluelight)] | ||
| Line 120: | Line 134: | ||
[[Category:Psychoactive substance]] | [[Category:Psychoactive substance]] | ||
[[Category:Research chemical]] | [[Category:Research chemical]] | ||
[[Category:Amphetamine]] | |||
[[Category:Benzofuran]] | |||
[[Category:Entactogen]] | [[Category:Entactogen]] | ||
[[Category:Stimulant]] | [[Category:Stimulant]] | ||